Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland.

Benjamin Philosophe, A. C. Farney, E. J. Schweitzer, J. O. Colonna, B. E. Jarrell, C. E. Foster, A. M. Wiland, S. T. Bartlett

Research output: Contribution to journalArticle

Abstract

The evolution of enteric and portal venous drainage, better immunosuppression, and better patient care has elevated pancreas transplantation with dramatically improved results. At our center, long-term graft survival and rejection has significantly improved with portal venous drainage, which has become our gold standard. This improvement is exemplified by the excellent one-year patient and graft survival rates for SPLK transplants. SPLK has proven to be an ideal approach in uremic Type 1 diabetic patients with living donors and should become the procedure of choice for that population. Moreover, the improved monitoring of rejection has allowed a similar success of pancreas transplantation alone in non-uremic patients with brittle diabetes. The treatment of diabetes mellitus has room for great improvement, however, and there is no question that islet transplantation, xenotransplantation, and the pursuit of immunologic tolerance will play an extremely important role in that endeavor.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
JournalClinical transplants
StatePublished - 2000
Externally publishedYes

Fingerprint

Living Donors
Kidney Transplantation
Pancreas
Pancreas Transplantation
Graft Survival
Kidney
Drainage
Islets of Langerhans Transplantation
Heterologous Transplantation
Graft Rejection
Immunosuppression
Patient Care
Diabetes Mellitus
Survival Rate
Transplants
Population
Therapeutics

Cite this

Philosophe, B., Farney, A. C., Schweitzer, E. J., Colonna, J. O., Jarrell, B. E., Foster, C. E., ... Bartlett, S. T. (2000). Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland. Clinical transplants, 211-216.

Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland. / Philosophe, Benjamin; Farney, A. C.; Schweitzer, E. J.; Colonna, J. O.; Jarrell, B. E.; Foster, C. E.; Wiland, A. M.; Bartlett, S. T.

In: Clinical transplants, 2000, p. 211-216.

Research output: Contribution to journalArticle

Philosophe, B, Farney, AC, Schweitzer, EJ, Colonna, JO, Jarrell, BE, Foster, CE, Wiland, AM & Bartlett, ST 2000, 'Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland.', Clinical transplants, pp. 211-216.
Philosophe, Benjamin ; Farney, A. C. ; Schweitzer, E. J. ; Colonna, J. O. ; Jarrell, B. E. ; Foster, C. E. ; Wiland, A. M. ; Bartlett, S. T. / Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland. In: Clinical transplants. 2000 ; pp. 211-216.
@article{59643193180447608a5d8646ee604229,
title = "Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland.",
abstract = "The evolution of enteric and portal venous drainage, better immunosuppression, and better patient care has elevated pancreas transplantation with dramatically improved results. At our center, long-term graft survival and rejection has significantly improved with portal venous drainage, which has become our gold standard. This improvement is exemplified by the excellent one-year patient and graft survival rates for SPLK transplants. SPLK has proven to be an ideal approach in uremic Type 1 diabetic patients with living donors and should become the procedure of choice for that population. Moreover, the improved monitoring of rejection has allowed a similar success of pancreas transplantation alone in non-uremic patients with brittle diabetes. The treatment of diabetes mellitus has room for great improvement, however, and there is no question that islet transplantation, xenotransplantation, and the pursuit of immunologic tolerance will play an extremely important role in that endeavor.",
author = "Benjamin Philosophe and Farney, {A. C.} and Schweitzer, {E. J.} and Colonna, {J. O.} and Jarrell, {B. E.} and Foster, {C. E.} and Wiland, {A. M.} and Bartlett, {S. T.}",
year = "2000",
language = "English (US)",
pages = "211--216",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Simultaneous pancreas-kidney (SPK) and pancreas living-donor kidney (SPLK) transplantation at the University of Maryland.

AU - Philosophe, Benjamin

AU - Farney, A. C.

AU - Schweitzer, E. J.

AU - Colonna, J. O.

AU - Jarrell, B. E.

AU - Foster, C. E.

AU - Wiland, A. M.

AU - Bartlett, S. T.

PY - 2000

Y1 - 2000

N2 - The evolution of enteric and portal venous drainage, better immunosuppression, and better patient care has elevated pancreas transplantation with dramatically improved results. At our center, long-term graft survival and rejection has significantly improved with portal venous drainage, which has become our gold standard. This improvement is exemplified by the excellent one-year patient and graft survival rates for SPLK transplants. SPLK has proven to be an ideal approach in uremic Type 1 diabetic patients with living donors and should become the procedure of choice for that population. Moreover, the improved monitoring of rejection has allowed a similar success of pancreas transplantation alone in non-uremic patients with brittle diabetes. The treatment of diabetes mellitus has room for great improvement, however, and there is no question that islet transplantation, xenotransplantation, and the pursuit of immunologic tolerance will play an extremely important role in that endeavor.

AB - The evolution of enteric and portal venous drainage, better immunosuppression, and better patient care has elevated pancreas transplantation with dramatically improved results. At our center, long-term graft survival and rejection has significantly improved with portal venous drainage, which has become our gold standard. This improvement is exemplified by the excellent one-year patient and graft survival rates for SPLK transplants. SPLK has proven to be an ideal approach in uremic Type 1 diabetic patients with living donors and should become the procedure of choice for that population. Moreover, the improved monitoring of rejection has allowed a similar success of pancreas transplantation alone in non-uremic patients with brittle diabetes. The treatment of diabetes mellitus has room for great improvement, however, and there is no question that islet transplantation, xenotransplantation, and the pursuit of immunologic tolerance will play an extremely important role in that endeavor.

UR - http://www.scopus.com/inward/record.url?scp=0034570515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034570515&partnerID=8YFLogxK

M3 - Article

C2 - 11512315

AN - SCOPUS:0034570515

SP - 211

EP - 216

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -